Literature DB >> 15720937

The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence.

Steven Simoens1, Catriona Matheson, Christine Bond, Karen Inkster, Anne Ludbrook.   

Abstract

BACKGROUND: Opiate dependence is a major health and social issue in many countries. A mainstay of therapy has been methadone maintenance treatment, but other treatments, particularly buprenorphine, are increasingly being considered. AIM: To conduct a systematic review to synthesise and critically appraise the evidence on the effectiveness of community maintenance programmes with methadone or buprenorphine in treating opiate dependence.
METHOD: A systematic review of databases, journals and the grey literature was carried out from 1990-2002. Inclusion criteria were: community-based, randomised controlled trials of methadone and/or buprenorphine for opiate dependence involving subjects who were aged 18 years old or over.
RESULTS: Trials were set in a range of countries, employed a variety of comparators, and suffered from a number of biases. The evidence indicated that higher doses of methadone and buprenorphine are associated with better treatment outcomes. Low-dose methadone (20 mg per day) is less effective than buprenorphine (2-8 mg per day). Higher doses of methadone (>50-65 mg per day) are slightly more effective than buprenorphine (2-8 mg per day). There was some evidence that primary care could be an effective setting to provide this treatment, but such evidence was sparse.
CONCLUSION: The literature supports the effectiveness of substitute prescribing with methadone or buprenorphine in treating opiate dependence. Evidence is also emerging that the provision of methadone or buprenorphine by primary care physicians is feasible and may be effective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15720937      PMCID: PMC1463190     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  51 in total

1.  A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence.

Authors:  J Pérez de los Cobos; S Martin; A Etcheberrigaray; J Trujols; F Batlle; A Tejero; J M Queraltó; M Casas
Journal:  Drug Alcohol Depend       Date:  2000-06-01       Impact factor: 4.492

2.  Buprenorphine: a controlled clinical trial in the treatment of opioid dependence.

Authors:  P P Pani; I Maremmani; R Pirastu; A Tagliamonte; G L Gessa
Journal:  Drug Alcohol Depend       Date:  2000-07-01       Impact factor: 4.492

3.  Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study.

Authors:  C Uehlinger; J Déglon; S Livoti; S Petitjean; D Waldvogel; D Ladewig
Journal:  Eur Addict Res       Date:  1998       Impact factor: 3.015

4.  Buprenorphine versus methadone maintenance for the treatment of opioid dependence.

Authors:  G Fischer; W Gombas; H Eder; R Jagsch; A Peternell; G Stühlinger; L Pezawas; H N Aschauer; S Kasper
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

5.  Additional methadone increases craving for heroin: a double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment.

Authors:  H V Curran; J Bolton; S Wanigaratne; C Smyth
Journal:  Addiction       Date:  1999-05       Impact factor: 6.526

6.  Thrice-weekly versus daily buprenorphine maintenance.

Authors:  R S Schottenfeld; J Pakes; P O'Connor; M Chawarski; A Oliveto; T R Kosten
Journal:  Biol Psychiatry       Date:  2000-06-15       Impact factor: 13.382

7.  Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance.

Authors:  K L Preston; A Umbricht; D H Epstein
Journal:  Arch Gen Psychiatry       Date:  2000-04

8.  A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.

Authors:  P G O'Connor; A H Oliveto; J M Shi; E G Triffleman; K M Carroll; T R Kosten; B J Rounsaville; J A Pakes; R S Schottenfeld
Journal:  Am J Med       Date:  1998-08       Impact factor: 4.965

9.  Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial.

Authors:  K L Sees; K L Delucchi; C Masson; A Rosen; H W Clark; H Robillard; P Banys; S M Hall
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

10.  Comparison of buprenorphine and methadone maintenance in opiate addicts.

Authors:  H Eder; G Fischer; W Gombas; R Jagsch; G Stühlinger; S Kasper
Journal:  Eur Addict Res       Date:  1998       Impact factor: 3.015

View more
  26 in total

1.  Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.

Authors:  Melanie S Askari; Silvia S Martins; Pia M Mauro
Journal:  J Subst Abuse Treat       Date:  2020-05-11

2.  Buprenorphine versus methadone--safety first?

Authors:  David Davies
Journal:  Br J Gen Pract       Date:  2005-03       Impact factor: 5.386

3.  Qualifications.

Authors:  Peter Gooderham
Journal:  Br J Gen Pract       Date:  2005-04       Impact factor: 5.386

4.  Is methadone too dangerous for opiate addiction?

Authors:  Jason Luty; Colin O'Gara; Mohammed Sessay
Journal:  BMJ       Date:  2005-12-10

5.  Methadone vs buprenorphine.

Authors:  Andrew Byrne; Richard Hallinan; Richard Watson; Alex Wodak
Journal:  Br J Gen Pract       Date:  2005-07       Impact factor: 5.386

Review 6.  Opioid dependence.

Authors:  Jacinta O'Shea; Fergus Law; Jan Melichar
Journal:  BMJ Clin Evid       Date:  2009-07-24

Review 7.  Opioid dependence.

Authors:  K Thyarappa Praveen; Fergus Law; Jacinta O'Shea; Jan Melichar
Journal:  BMJ Clin Evid       Date:  2011-09-20

8.  Clinical guideline for homeless and vulnerably housed people, and people with lived homelessness experience.

Authors:  Kevin Pottie; Claire E Kendall; Tim Aubry; Olivia Magwood; Anne Andermann; Ginetta Salvalaggio; David Ponka; Gary Bloch; Vanessa Brcic; Eric Agbata; Kednapa Thavorn; Terry Hannigan; Andrew Bond; Susan Crouse; Ritika Goel; Esther Shoemaker; Jean Zhuo Jing Wang; Sebastian Mott; Harneel Kaur; Christine Mathew; Syeda Shanza Hashmi; Ammar Saad; Thomas Piggott; Neil Arya; Nicole Kozloff; Michaela Beder; Dale Guenter; Wendy Muckle; Stephen Hwang; Vicky Stergiopoulos; Peter Tugwell
Journal:  CMAJ       Date:  2020-03-09       Impact factor: 8.262

Review 9.  Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.

Authors:  Jean Bonhomme; Ruth S Shim; Richard Gooden; Dawn Tyus; George Rust
Journal:  J Natl Med Assoc       Date:  2012 Jul-Aug       Impact factor: 1.798

10.  Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.

Authors:  T V Parran; C A Adelman; B Merkin; M E Pagano; R Defranco; R A Ionescu; A G Mace
Journal:  Drug Alcohol Depend       Date:  2009-08-29       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.